Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

Laser Angioplasty for AMI
The REVA Medical Bioresorbable Stent Program
Contemporary use of Thrombin Inhibitors
DES for LM: The Korean Experience-Ready for Prime Time?
Will the Registries Replace the Randomized DES Clinical Trials?



Vorapaxar and Stent Thrombosis

TRA 2°P-TIMI 50 demonstrated that vorapaxar, a thrombin receptor antagonist, reduces CV death and recurrent thrombotic events at the expense of increased bleeding. Further analysis has shown that vorapaxar also reduces stent thrombosis in patients with stable CAD.

For more, click here




TAVI for Bicuspid AV

The outcome of TAVI in patients with bicuspid AV stenosis is unknown. Analysis of data from 139 patients has indicated the relative safety and efficacy of TAVI in this population, but the incidence of post-implantation AR was high (28.4%). The latter could be reduced by utilization of multislice CT sizing.

For more, click here




Epinephrine and Cardiac Arrest Outcomes

Epinephrine is a commonly used drug during cardiac resuscitation. Analysis of data from 1556 out-of-hospital cardiac arrest patients has shown that the pre-hospital use of epinephrine may be associated with a lower chance of survival.

For more, click here




The Challenges of Moderate Ischemic MR

Ischemic mitral regurgitation (MR) is associated with increased morbidity and mortality. Whether ischemic MR should be repaired at the time of CABG is unknown. One-year data from a randomized study of 301 patients has indicated that the combination of CABG and mitral repair does not lead to improved LV reverse modeling. This approach was also associated with increased adverse events.

For more, click here



Untitled Document
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD
Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY Registry
- Felix Mahfoud, MD
SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months
- George L. Bakris, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives

Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial.
M Bonaca, et al.
JACC 2014; 64:2309-2317
Transcatheter Aortic Valve Replacement in Bicuspid Aortic Valve Disease.
D Mylotte, et al.
JACC 2014; 64:2330-2339
OCT Assessment of the Long-Term Vascular Healing Response 5 Years After Everolimus-Eluting Bioresorbable Vascular Scaffold.
A Karanasos, et al.
JACC 2014;64:2343-2356
Is Epinephrine During Cardiac Arrest Associated With Worse Outcomes in Resuscitated Patients?
F Dumas, et al.
JACC 2014; 64:2360-2367
Acute Kidney Injury After Coronary Artery Bypass Grafting and Long-Term Risk of End-Stage Renal Disease.
L Rydén, et al.
Circ 2014; 130:2005-2011
Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis: Mode, Incidence, and Impact on Outcome in a Large Cohort of Patients.
T Sénage, et al.
Circ 2014; 130:2012-2020
Assessment of Atherosclerosis in Chronic Granulomatous Disease.
C Sibley, et al.
Circ 2014; 130:2031-2039
Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations.
M Magalhaes, et al.
Circ Cardiovasc Interv 2014 Online
Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-Eluting Stents.
L Mauri, et al.
NEJM 2014; 371:2155-2166
Surgical Treatment of Moderate Ischemic Mitral Regurgitation.
P Smith, et al.
NEJM 2014; 371:2178-2188
Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury: A Randomized Clinical Trial.
A Garg, et al.
JAMA 2014; 312:2254-2264
Incidence, Angiographic Features and Outcomes of Patients Presenting With Subtle ST-Elevation Myocardial Infarction.
D Marti, et al.
AHJ 2014; 168:884-890

Poll Archives
Primary Outcomes of the EVOLVE II Trial
Dean J. Kereiakes, MD
| Watch CardioTube Interview
Dion Stub, MD
| Watch CardioTube Interview
C.Kaiser, MD, et al.
| Watch CardioTube Interview
Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the TAXUS Liberte Paclitaxel- Eluting Coronary Stent
Kirk N. Garratt, MD, et al.
| Watch CardioTube Interview
Six versus Twelve Months of Clopidogrel Therapy After Drug-Eluting Stenting - the Randomized, Double-Blind, Placebo-Controlled ISAR-SAFE Trial
Stefanie Schupke, MD, et al.
| Watch CardioTube Interview
Dual Antiplatelet Therapy Beyond One Year After Drug-eluting Coronary Stent Procedures
Laura Mauri, MD, et al.
| Watch CardioTube Interview
Randomized Trial of Atenolol Versus Losartan in Children and Young Adults with Marfan Syndrome
Ronald V. Lacro, MD, et al.
| Watch CardioTube Interview
FACTOR-64 Randomized Clinical Trial
Joseph Muhlestein, MD, et al.
| Watch CardioTube Interview
Results from the DAPT Study
Dean J. Kereiakes, MD
| Watch CardioTube Interview
IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
Christopher P. Cannon, MD, et al.
| Watch CardioTube Interview
Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: a randomized clinical trial
Kazuyuki Shimada, MD, et al.
| Watch CardioTube Interview
Final Results of the Regional Systems of Care Demonstration Project: Mission: Lifeline STEMI Accelerator Study
Matthew W. Sherwood, MD, et al.
Martine Gilard, MD, PhD, et al.
Anna Axelsson, MD, et al.
Impact of a Multidisciplinary Management Program on Recurrent Hospitalization and Mortality in Older Individuals With Chronic Atrial Fibrillation: A Multi-Center Randomized Trial
Simon Stewart, MD, et al.
John J.V. McMurray, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD

Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb